Ultragenyx Pharmaceutical Inc. provided earnings guidance for the year 2022. For the year, company expects Crysvita revenue in the Ultragenyx territories to be between $250 million and $260 million, representing growth of 33% year-over-year at the mid-point of guidance. Dojolvi revenue is estimated to be between $55 million and $65 million, representing growth of 60% year-over-year at the mid-point of guidance in the second year of launch.